Hypofractionation for prostate cancer: a word of caution

The Lancet Oncology

Volumn 17, Issue 4, 2016, Pages 406-407

  Bossi, Alberto ^a   Blanchard, Pierre ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CELL; CLINICAL EFFECTIVENESS; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; HYPOFRACTIONATED RADIOTHERAPY; NOTE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY CONTROL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; TREATMENT PLANNING; UROGENITAL TRACT DISEASE; MALE; PROSTATE TUMOR; RADIATION DOSE FRACTIONATION;

DOSE FRACTIONATION; DOSE HYPOFRACTIONATION; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84959925807     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00626-9     Document Type: Note

References (7)

1. 1 Dasu, A, Toma-Dasu, I, Prostate alpha/beta revisited: an analysis of clinical results from 14 168 patients. Acta Oncol Stockh Swed 51 (2012), 963–974.
2. 2 Koontz, BF, Bossi, A, Cozzarini, C, et al. A systematic review of hypofractionation for primary management of prostate cancer. Eur Urol 68 (2015), 683–691.
3. 3 Lee, WR, Dignam, JJ, Amin, M, et al. NRG Oncology RTOG 0415: A Randomized Phase 3 Noninferiority Study Comparing 2 Fractionation Schedules in Patients With Low-Risk Prostate Cancer. Int J Radiat Oncol 94 (2015), 3–4.
4. 4 Wilkins, A, Mossop, H, Syndikus, I, et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 16 (2015), 1605–1616.
5. 5 Aluwini, S, Pos, F, Schimmel, E, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol, 2016 published online March 8. http://dx.doi.org/10.1016/S1470-2045(15)00567-7.
6. 6 Incrocci, L, Wortel, RC, Aluwini, S, et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five-year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. Int J Radiat Oncol 94 (2015), 1–2.
7. 4 Aluwini, S, Pos, F, Schimmel, E, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. Lancet Oncol 16 (2015), 274–283.